NAUTNautilus Biotechnology, Inc.

NAUT Stock Price, Valuation & Chart | Nautilus Biotechnology, Inc.

Compare

$0.960+0.04 (+3.81%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology NAUT intrinsic value NAUT calculated fair value vs price

Overview Financials Dividends Ratios

NAUT Historical price chart

NAUT Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization122.39M

PE Ratio-2.09

EPS-0.46

Trading Volume834.74K

Today's High/Low0.99/0.92

Dividend Yield0.00

52 Week High/Low4.31/0.62

Shares Outstanding127.26M

NAUT Financial Statement

NAUT Analyst ratings

NAUT Analysis & performance metrics

NAUT Company profile

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the…

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in…

NAUT Management team

Name

Position

Gwen E. Weld

Chief People Officer

Subra Sankar Ph.D.

Senior Vice President of Product Development

Anna MowryCFO

Chief Financial Officer & Treasurer

Matthew B. Murphy ESQ.

General Counsel

Kentaro Suzuki

Chief Marketing Officer

Parag Mallick Ph.D.CTO

Co-Founder, Chief Scientist & Director

Sujal M. PatelCEO

Co-Founder, Chief Executive Officer, President, Secretary & Director

Name

Position

Gwen E. Weld

Chief People Officer

Subra Sankar Ph.D.

Senior Vice President of Product Development

Anna MowryCFO

Chief Financial Officer & Treasurer

Matthew B. Murphy ESQ.

General Counsel

Kentaro Suzuki

Chief Marketing Officer

Parag Mallick Ph.D.CTO

Co-Founder, Chief Scientist & Director

Sujal M. PatelCEO

Co-Founder, Chief Executive Officer, President, Secretary & Director

Management Team

Gwen E. Weld

Chief People Officer

Subra Sankar Ph.D.

Senior Vice President of Product Development

Anna MowryCFO

Chief Financial Officer & Treasurer

Matthew B. Murphy ESQ.

General Counsel

Kentaro Suzuki

Chief Marketing Officer

Parag Mallick Ph.D.CTO

Co-Founder, Chief Scientist & Director

Sujal M. PatelCEO

Co-Founder, Chief Executive Officer, President, Secretary & Director

Management

Gwen E. Weld

Chief People Officer

Subra Sankar Ph.D.

Senior Vice President of Product Development

Anna MowryCFO

Chief Financial Officer & Treasurer

Matthew B. Murphy ESQ.

General Counsel

Kentaro Suzuki

Chief Marketing Officer

Parag Mallick Ph.D.CTO

Co-Founder, Chief Scientist & Director

Sujal M. PatelCEO

Co-Founder, Chief Executive Officer, President, Secretary & Director

Total 7 executives

NAUT Frequently asked questions

What is Nautilus Biotechnology, Inc. (NAUT) Stock Price?

Current stock price of Nautilus Biotechnology, Inc. (NAUT) stock is $0.960. The stock price is +3.81% higher in the session. The intraday range can be seen from this page. Volume of Nautilus Biotechnology, Inc. (NAUT) stock is 834.74K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Nautilus Biotechnology, Inc. (NAUT) stock price going up or down today?

The stock price of Nautilus Biotechnology, Inc. (NAUT) can change with earnings, company news, and overall market sentiment. Nautilus Biotechnology, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Nautilus Biotechnology, Inc. stock expensive at its current price?

Whether Nautilus Biotechnology, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for NAUT on this page is -2.09. EPS on this page is -0.46. Compare those figures with peers and growth expectations before deciding if the current Nautilus Biotechnology, Inc. price is justified.

How has the stock price of Nautilus Biotechnology, Inc. (NAUT) performed historically?

Historical performance for Nautilus Biotechnology, Inc. (NAUT) is shown on the price chart on this page. Review multi-period moves alongside volume to see how NAUT reacted to past earnings and market events.

Should I buy Nautilus Biotechnology, Inc. (NAUT) stock, at this price?

Buying Nautilus Biotechnology, Inc. (NAUT) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.